Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dositinib mesylate (90-1408) in EGFR-mutated advanced NSCLC
ChiCTR2000039281Phase 2Recruiting
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Aug 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of dositinib mesylate in EGFR-mutated non-small cell lung cancer and non-small cell lung cancer (NSCLC) (2 arms), sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Primary endpoint: Safety and tolerability indicators. Started Aug 2020; status: recruiting.
02
Drugs
dositinib mesylate
03
Conditions
EGFR-mutated non-small cell lung cancernon-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2000039281.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000039281.